EyePoint Pharmaceuticals Q3 2022 Earnings Report
Key Takeaways
EyePoint Pharmaceuticals reported a strong quarter with the initiation of two Phase 2 clinical trials for EYP-1901 in wet AMD and NPDR, along with net product revenue of $9.7 million, a 13% increase from Q3 2021.
Initiated Phase 2 DAVIO 2 clinical trial for wet age-related macular degeneration (wet AMD) and Phase 2 PAVIA clinical trial for non-proliferative diabetic retinopathy (NPDR).
Presented positive twelve-month safety and efficacy data from Phase 1 DAVIO clinical trial for EYP-1901 in wet AMD at American Society of Retina Specialists (ASRS) 2022 Annual Meeting and American Academy of Ophthalmology (AAO) 2022 Annual Meeting.
Net product revenue of $9.7 million in Q3 2022; a 13% increase from Q3 2021.
The first patient was dosed in the Phase 2 PAVIA clinical trial of EYP-1901 for the treatment of NPDR in September 2022.
EyePoint Pharmaceuticals
EyePoint Pharmaceuticals
EyePoint Pharmaceuticals Revenue by Segment
Forward Guidance
The company expects its cash, cash equivalents, and investments on hand, along with expected net cash inflows from product sales, to fund current and planned operations into the second half of 2024.
Revenue & Expenses
Visualization of income flow from segment revenue to net income